Lupin's generic tolvaptan tablets are now FDA-approved for treating autosomal dominant polycystic kidney disease (ADPKD).

Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Latest News
We spoke to David M. Hume Award winner Bradley Warady, MD, at the National Kidney Foundation Spring Clinical Meetings 2025.
Joel Topf spoke to onconephrologist Meghan Sise about her carboplatin dosing research at SCM25.
Joel Topf caught up with James Tumlin at NKF SCM25 to talk about Dr. Tumlin's late-breaking abstract on sparsentan in FSGS.
This Freely Filtered episode discusses REGENCY, examining the efficacy and safety of obinutuzumab in active lupus nephritis.
Joel Topf spoke with Lazarus Award winner Jeffrey Perl at the National Kidney Foundation Spring Clinical Meetings 2025.
Joel Topf spoke with Connie Rhee at SCM25 about her study on cognitive function with dialysis vs conservative CKD management.
Joel Topf spoke with Bradley Marder of Amgen about gout studies at the NKF Spring Clinical Meetings 2025.
A survey sought insight on nephrologists' practices and perceptions about reproductive care for women with kidney disease.
Joel Topf spoke to Excellence in Transplantation Award winner Jayme Locke at the National Kidney Foundation SCM25.
A study examined the effects of SGLT2i on eGFR slope in patients with autosomal dominant polycystic kidney disease.
Advertisement
Expert Interviews
Conferences
Podcasts
This Freely Filtered episode discusses REGENCY, examining the efficacy and safety of obinutuzumab in active lupus nephritis.
Listen to the discussion of Chapter 18 of Dr. Burton Rose's book, focused on metabolic alkalosis.
Freely Filtered returns with another episode for NephMadness, this time, covering the hemodialysis region.
The Freely Filtered Filtrate discusses the top nephrology stories of 2024, including FLOW, cyberattacks, and IgAN trials.
Expert Columns
Ajay Singh discusses the state of rare kidney disease research.
Sarah Tolson highlights the concerns and challenges dialysis programs face under the 2025 ESRD PPS requirements.
Dr. Ajay Singh and others pay tribute to Dr. Barry Brenner, a leading nephrologist who passed away in August 2024.
Sarah Tolson shares what billing departments of dialysis programs need to know about the CMS final rule for the ESRD PPS.
It is important to understand the challenges Medicare Advantage plans present for ESRD care.
Dr. Ajay Singh discusses the reasons why medical students and residents are not choosing to pursue careers in nephrology.